Cite

HARVARD Citation

    Tolaney, S. et al. (2017). Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients. Oncologist. pp. 25-32. [Online]. 
  
Back to record